Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5045748 | 0.94 | ESR1 (0.37) | LSSESR1GABRPGABRDGABRA1 | |
| SCHEMBL5045659 | 0.89 | ESR1 (0.38) | LSSESR1MAPK14KIF11KDR | |
| SCHEMBL7144742 | 0.88 | ESR1 (0.35) | LSSESR1GABRPGABRDGABRA1 | |
| SCHEMBL5038033 | 0.88 | LSS (0.54) | LSSESR1 | |
| SCHEMBL7167944 | 0.86 | LSS (0.32) | LSSESR1 | |
| SCHEMBL5038830 | 0.86 | LSS (0.45) | LSSESR1 | |
| SCHEMBL5038989 | 0.84 | ESR1 (0.36) | ESR1KIF11KDR | |
| SCHEMBL5038354 | 0.84 | LSS (0.36) | LSSESR1 | |
| SCHEMBL5038356 | 0.83 | ESR1 (0.31) | ESR1 | |
| SCHEMBL5038930 | 0.83 | ESR1 (0.32) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449483-B2 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | AEBI JOHANNES | 2007-05-03 | — | — | US | disclosed |
| US-7173043-B2 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | AEBI JOHANNES | 2005-12-01 | — | — | US | disclosed |
| US-6951879-B2 | Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1334094-B1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1334094-A1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-13 | — | — | EP | disclosed |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. | 2002-07-04 | — | — | US | disclosed |
| WO-2002036584-A1 | CHOLESTEROL LOWERING BENZO`B! THIOPHENES AND BENZO`D! ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | LSS, CYP51A1, CYP46A1 | LSS 1/4885ESR1 2592/4885GABRP 4508/4885 |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | LSS 1/4885ESR1 1155/4885GABRP 3335/4885 |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | LSS 1/4885ESR1 1155/4885GABRP 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.